Kotak’s alternative investment fund pumps in ₹1,070 cr in Biocon. Details here

  • Biocon plans to utilise the proceeds for financing its subsidiary Biocon Biologics' acquisition of the biosimilars business of its partner Viatris to create a global vertically integrated biosimilars player.

Pooja Sitaram Jaiswar
Updated22 Feb 2023, 08:02 PM IST
Kotak Special Situations Fund (KSSF) is an Alternative Investment Fund under SEBI regulations managed by Kotak Investment Advisors.
Kotak Special Situations Fund (KSSF) is an Alternative Investment Fund under SEBI regulations managed by Kotak Investment Advisors.

Kotak Special Situations Fund (KSSF) on Wednesday announced an investment of a whopping RS 1,070 crore in Indian biopharmaceutical major, Biocon. The Bangalore-based pharma company plans to utilise the proceeds for financing its subsidiary Biocon Biologics' acquisition of the biosimilars business of its partner Viatris to create a global vertically integrated biosimilars player.

In a statement, Srini Sriniwasan, managing director, of Kotak Investment Advisors Limited said, “This investment in Biocon comes at a pivotal point when Biocon is forward integrating its biosimilars business. Going forward Biocon will realize full revenues and profits from this business."

Sriniwasan added, "With this, the USD 1 billion Kotak Special Situations Fund is fully committed. India continues to offer unique and attractive risk-adjusted opportunities for hybrid funding strategies.”

Further, Eshwar Karra, CEO – of Kotak Special Situations Fund at Kotak Investment Advisors Limited said, “We are delighted to partner with Biocon and this acquisition financing supports Biocon’s journey of becoming a world-leading, fully integrated biosimilars enterprise.”

On BSE, Biocon's share price closed at 222.15 apiece down by 2.16%. The downside came in amidst a broader bearish market. The company's market cap is over 26,671 crore by end of February 22nd.

In Q3FY23, Biocon registered a net loss of 42 crore as against a profit of 187 crore in the same quarter last year, due to an exceptional item of 271 crore owing to Viatris deal-related expenses. On the other hand, Biocon's revenue from operations climbed 35% to 2,941 crore in Q3FY23, compared with 2,174 crore a year ago same quarter.

On February 14, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics in Q3 financial report said, "Q3 FY23 has been an eventful quarter which saw the completion of the global acquisition of our partnered Biosimilars business from Viatris on Nov 29, 2022. We are now implementing country-wise integration of the business to maximize the value of the combined entity to propel growth. Biosimilars as a business segment offers differentiated growth to Biocon Biologics based on vertical integration and a unique portfolio of Insulins and antibody-based immunotherapeutics. This quarter captures a fraction of the acquired business, but from Q4FY23 onwards, the financials will recognise the entire Biosimilars business."

While Biocon Biologics MD Shreehas Tambe said, the company recorded its highest-ever quarterly revenue of 1,507 crore, reflecting a growth of 54% on the back of its acquisition of Viatris' biosimilars business and continued growth in BBL-led markets.

Last year, in November, Biocon Biologics successfully completed its multi-billion-dollar acquisition of the global biosimilars business of its partner Viatris. This acquisition gives Biocon Biologics direct commercial capabilities and supporting infrastructure in the advanced markets and several emerging markets, bringing it closer to patients, customers, and payors.

Biocon is an innovation-led global bio-pharmaceuticals company that has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and global markets and, generic formulations in US and Europe.

While Biocon Biologics (BBL), a subsidiary of Biocon, is a fully integrated global biosimilars company that has commercialized eight biosimilars in key emerging and advanced markets such as the US and Europe and has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, and other non-communicable diseases. It has many ‘firsts’ to its credit in the biosimilars industry.

Kotak Special Situations Fund (KSSF) is an Alternative Investment Fund under SEBI regulations managed by Kotak Investment Advisors.

Currently, KSSF manages a $1 billion fund and is uniquely positioned to be a provider of customized solution capital to corporates. KSSF has been targeting value propositions across a spectrum of opportunities, from growth to credit situations and stressed assets.

Catch all the Budget News , Business News , Corporate news , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.

MoreLess
First Published:22 Feb 2023, 08:02 PM IST
HomeCompaniesNewsKotak’s alternative investment fund pumps in ₹1,070 cr in Biocon. Details here

Get Instant Loan up to ₹10 Lakh!

  • Employment Type

    Most Active Stocks

    Bharat Electronics

    313.55
    11:09 AM | 23 JUL 2024
    0.95 (0.3%)

    Tata Steel

    160.40
    11:09 AM | 23 JUL 2024
    0.05 (0.03%)

    Federal Bank

    199.10
    11:09 AM | 23 JUL 2024
    6.15 (3.19%)

    Vedanta

    432.60
    11:09 AM | 23 JUL 2024
    -16.25 (-3.62%)
    More Active Stocks

    Market Snapshot

    • Top Gainers
    • Top Losers
    • 52 Week High

    Easy Trip Planners

    43.00
    11:04 AM | 23 JUL 2024
    2.95 (7.37%)

    Rajesh Exports

    313.20
    11:02 AM | 23 JUL 2024
    15.65 (5.26%)

    Suzlon Energy

    57.78
    11:04 AM | 23 JUL 2024
    2.71 (4.92%)

    Glaxosmithkline Pharmaceuticals

    2,723.80
    11:04 AM | 23 JUL 2024
    105.1 (4.01%)
    More from Top Gainers

    Recommended For You

      More Recommendations

      Gold Prices

      • 24K
      • 22K
      Bangalore
      75,195.00-315.00
      Chennai
      75,122.00-535.00
      Delhi
      75,048.00-169.00
      Kolkata
      75,561.00417.00

      Fuel Price

      • Petrol
      • Diesel
      Bangalore
      102.86/L0.00
      Chennai
      100.75/L-0.23
      Kolkata
      104.95/L0.00
      New Delhi
      94.72/L0.00
      OPEN IN APP
      HomeMarketsCibilPremiumBudget